Perimenopause: The Hormonal Transition Women Were Taught to Endure in Silence

I am a man writing about a transition I have not lived. I want to name that before we go any further, because the women I work with notice when a man does not. What I bring to this conversation is not first-person experience. It is thirty years inside the traditions that have studied this transition longer than modern medicine has been a discipline.

In Ayurveda, the foundational texts on women's reproductive medicine — Charaka's Samhita, Sushruta's Samhita, Vagbhata's Ashtanga Hridayam — were all written by male physicians more than two thousand years ago, and they are still the spine of any contemporary Ayurvedic perimenopause practice. In Traditional Chinese Medicine, the Huangdi Neijing Su Wen mapped the seven-year cycles of women's reproductive life nearly twenty-three centuries ago; Qian Yi codified Liu Wei Di Huang Wan in the Song dynasty around 1119 CE — still the foundational kidney-yin tonifying formula for perimenopausal hot flashes today; Zhang Jiebin in the Ming dynasty wrote You Gui Wan and Zuo Gui Wan, still in clinical use; Fu Qingzhu wrote Fu Qingzhu Nü Ke, the canonical Chinese-medicine gynecology text, in the seventeenth century. Each of these men was the architect of a women's-medicine framework that women themselves still rely on. And in modern yoga, BKS Iyengar — the lineage holder who explicitly directed the development of women-specific yoga practice through his daughter Geeta — wrote the foreword to her A Gem for Women, the foundational modern text on women's yoga across the life stages, and championed her sequencing for menstruation, pregnancy, and menopause when much of the yoga world still pretended women's bodies did not need adaptation. Krishnamacharya and his son T. K. V. Desikachar belong to the same lineage of male teachers whose work made women's yoga therapy possible.

I am not claiming to be in their company. I am claiming the same posture they held: a man writing for the integrity of a practice that includes women's specific physiology. The contemporary medical equivalent is Dr. Avrum Bluming, the male oncologist who co-authored Estrogen Matters with Carol Tavris and who has done as much as any clinician alive to clarify what the WHI data actually showed.

And I bring the hundreds of women I have sat with in retreats in Marbella, in India, in Thailand, and in 1:1 practice over the last two decades — women who arrived exhausted, dismissed by clinicians, told their symptoms were stress, and who found, in a framework that combined modern endocrinology with the older systems, a way through that did not depend on enduring or on a single pharmaceutical intervention. The pattern I have watched repeat across cohorts is consistent enough to write down. That is what this article is.

This is the version of perimenopause I wish every woman were given when she walked into her first appointment about it. It is long. The depth is the point. If you are a woman between 40 and 60 — or you love one — read it slowly.

What is perimenopause? The hormonal transition before menopause

Perimenopause is the multi-year hormonal transition that precedes menopause. The internationally accepted staging system, STRAW+10 (Stages of Reproductive Aging Workshop, updated 2011), defines it as beginning with the first variability in cycle length and detectable rise in FSH (Stage -2), continuing through the first twelve months after the final menstrual period (Stage +1a). The full transition typically lasts four to ten years and can extend longer.

Menopause itself is a point — twelve consecutive months without a menstrual period. Perimenopause is the years of fluctuation leading up to that point. The crucial clinical distinction: it is the fluctuation, not the eventual decline, that produces most of the disruptive symptoms women associate with this stage of life. The hormonal landscape of perimenopause is not a smooth descent. It is dysregulation.

The largest and longest-running study of this transition is the SWAN Study — the Study of Women's Health Across the Nation — which began enrolling 3,302 pre- and early-perimenopausal women across seven US sites in 1996 and has now followed many of them for more than twenty years. SWAN data, more than any other single source, defines what we know about how this transition unfolds in real women.

The International Menopause Society's 2024 White Paper (Panay et al., Climacteric, 2024) confirms an important clinical nuance: distressing symptoms often begin before women technically enter perimenopause as defined by STRAW+10 — that is, in the late reproductive stage (Stage -3) when cycles are still regular but the hormonal milieu has already begun to shift. Women whose symptoms begin then are routinely told they are too young for perimenopause. They are not. They are early.

At what age does perimenopause start? Hormonal shifts by decade

For most women, perimenopause begins in the mid-40s — the median onset in SWAN data sits around age 47 — but the late reproductive stage that precedes it can begin in the early 40s, and a meaningful minority of women enter the transition earlier. Race and ethnicity matter here: SWAN consistently shows that Black and Hispanic women enter perimenopause earlier than White, Chinese, and Japanese women, and experience vasomotor symptoms more severely and for longer.

The duration is striking. Gibson and colleagues, summarising SWAN data in Menopause (2024), reported a median total duration of vasomotor symptoms of 7.4 years among women who experienced frequent hot flashes — and 11.8 years among women whose symptoms began in early perimenopause. SWAN has documented vasomotor symptoms persisting up to fourteen years in some women. This is not a short event. This is a substantial chapter of the adult female life.

The hormonal landscape shifts in a specific sequence. Progesterone is the first hormone to decline meaningfully — sometimes years before estrogen shows any net change. The reason is mechanical. In the late reproductive stage, ovulatory cycles become irregular and anovulatory cycles (cycles without ovulation) increase. Without ovulation, the corpus luteum does not form, and progesterone is not produced in the second half of the cycle. This early progesterone loss is the biochemical engine of the early perimenopausal symptom cluster: anxiety that did not used to be there, sleep that fragments, mood instability, and increasingly heavy or irregular periods — symptoms that are often misread as stress.

Estradiol, by contrast, does not simply decline. It oscillates — and often surges to levels higher than premenopausal norms in early perimenopause, before falling. Grub and colleagues (2021) summarised the modern view: estradiol levels fluctuate widely and even rise during the transition. These estradiol surges produce breast tenderness, bloating, headaches, and heavy bleeding. Only in late perimenopause (Stage -1, with gaps of sixty days or more between periods) does estradiol show a sustained net fall.

FSH — follicle-stimulating hormone — rises as the ovaries become progressively less responsive to pituitary signaling. FSH elevation is one of the earliest measurable markers of the transition, though its day-to-day variability makes it unreliable as a stand-alone diagnostic.

The hypothalamic-pituitary-ovarian (HPO) axis as a whole shifts to a new set point. The hypothalamus increases GnRH pulse frequency, the pituitary responds with elevated LH and FSH, and the aging ovarian follicle pool diminishes in quality and quantity, reducing the negative feedback that once held the axis steady. The perimenopausal HPO axis is destabilised. This is the biological substrate of the wild hormonal swings women describe — and it is fundamentally different from andropause, where the hormonal change in men is gradual and unidirectional.

Perimenopause symptoms: the full cluster

Roughly 81% of perimenopausal women report meaningful symptoms (Choudhary et al., 2025, PMC12431706). Up to 80% experience vasomotor symptoms (hot flashes and night sweats). And recent survey data from Monash University (2025) found that approximately 40% of women in the transition have untreated and potentially debilitating symptoms. The symptoms are real, prevalent, and under-treated.

Here is the full cluster, organised by system.

Cycles and bleeding

Irregular cycles are the defining early sign. Cycles shorten first, then lengthen, then become unpredictable. Many women experience heavier bleeding in early perimenopause — driven by relative estrogen excess without the modulating effect of progesterone. This early-perimenopause heavy bleeding pattern is what Ayurveda calls asrigdara, and is one of the primary uses of the herb ashoka (Saraca asoca) in classical practice.

Vasomotor symptoms — hot flashes and night sweats

The most-studied symptom cluster, affecting up to 80% of women. The mechanism is now understood in detail. The work of Naomi Rance and her colleagues at the University of Arizona, summarised in Frontiers in Neuroendocrinology (Rance et al., 2013), identified the cell type at the centre of the hot flash: the KNDy neurons — kisspeptin, neurokinin B, and dynorphin-producing neurons in the hypothalamic infundibular (arcuate) nucleus. Under stable estrogen levels, estrogen suppresses KNDy neuron activity. As estrogen declines, the neurons hypertrophy and hyperactivate, releasing neurokinin B that binds NK3 receptors on adjacent thermoregulatory neurons, triggering peripheral vasodilation, sweating, and the upward rush of heat.

This is not a metaphorical mechanism. It is the reason fezolinetant (Veozah) works. Fezolinetant — an NK3 receptor antagonist that directly blocks the KNDy signal — was the first non-hormonal pharmaceutical specifically designed to target this mechanism. FDA-approved in May 2023 and EMA-approved later that year, the SKYLIGHT 1 and SKYLIGHT 2 Phase 3 trials (Lederman et al., The Lancet, 2023) showed reductions in hot flash frequency of around 1.8 per day over twelve weeks. It is not a cure, but it is the first pharmacological non-hormonal option grounded in the actual mechanism.

There is also a non-pharmacological intervention with randomised-controlled evidence that targets the same physiology from the opposite direction: slow-paced respiration. Sood and colleagues at the Mayo Clinic (Menopause, 2013) demonstrated that paced breathing at approximately six breaths per minute — the same rate that pranayama traditions converged on independently — reduces hot flash frequency. The mechanism: vagal/parasympathetic engagement widens the thermoregulatory zone the KNDy neurons fail to anchor. Ancient practice, modern trial, same target.

Sleep

Sleep disruption affects 40 to 60% of women in the transition. Night sweats fragment sleep directly, but the disruption is not solely secondary to vasomotor symptoms. Hormonal changes independently alter sleep architecture — slow-wave sleep becomes fragmented and de-anchored from its normal early-night timing (Tamanna et al., 2026; Troìa et al., 2025, PMC11901009). Sahola et al. (Maturitas, 2024) directly linked worse objective sleep architecture to higher cortisol levels, drawing the line from hormonal shift to HPA axis to sleep quality.

Mood: depression, anxiety, and rage

Up to 70% of women experience meaningful mood symptoms during perimenopause (NIH StatPearls, 2026). The mechanism is neurobiological, not psychological. Estrogen modulates serotonin receptor expression and serotonin transporter activity — fluctuating estrogen destabilises serotonin signaling, producing dysphoria and tearfulness. Progesterone and its metabolite allopregnanolone are positive allosteric modulators of the GABA-A receptor, providing a natural anxiolytic, calming effect. When progesterone falls in early perimenopause, that GABA tone is lost — and what arrives is anxiety, the inability to switch off, and the specific affective intensity of the early transition.

The rage cluster has its own neurobiology. Estrogen drop reduces norepinephrine regulation and increases amygdala reactivity; progesterone loss strips GABA-mediated calming; the threshold for anger, frustration, and emotional flooding drops. This is neurological. It is not a character flaw. Hynd and colleagues (2024, PMC12035911) found, on functional neuroimaging, that women with perimenopause-onset depression showed increased resting-state connectivity between the right amygdala and other brain regions — biological evidence of what the women have been telling clinicians for decades.

Cognition and brain fog

This is where the work of Dr. Lisa Mosconi, director of the Women's Brain Initiative at Weill Cornell Medicine, has transformed the field. Mosconi's neuroimaging studies (2021, 2024) show substantial changes in brain structure, gray matter volume, connectivity, and energy metabolism across the menopausal transition. Her most striking finding: brain glucose metabolism — the brain's primary fuel system — can drop by up to 30% during perimenopause and menopause. Estrogen is a metabolic signal for the brain. When it falls, the brain loses efficiency. This is the substrate of brain fog, word-finding difficulty, and slowed processing speed. It is not psychosomatic.

Mosconi's research also establishes the longer-term stakes. Women account for two-thirds of all Alzheimer's cases, and that risk differential begins in midlife hormonal transition — not in old age. Early Alzheimer's biomarkers can appear on neuroimaging in perimenopausal women before any clinical symptoms. This makes perimenopause, in her phrase, "the front line of Alzheimer prevention" (Mosconi, JCI, 2026).

Body composition: visceral fat and muscle loss

Estrogen regulates fat distribution. As it declines, fat redistributes centrally — visceral adipose tissue accumulates around the abdominal organs. This is not a caloric problem. Younglove et al. (2026) confirmed that the perimenopausal body composition shift is independent of caloric intake. Simultaneously, estrogen has direct anabolic signaling in skeletal muscle via estrogen receptors on satellite cells; its loss accelerates age-related muscle loss. Cho and colleagues (2025, PMC12567333) named this combined pattern "sarcopenic obesity" — the central fat gain and muscle loss that, together, drive insulin resistance and a self-compounding cycle.

Bone density

Bone loss accelerates sharply in the two years before and two years after the final menstrual period — the period of steepest estrogen decline. Bone loss can reach 2-3% per year during this window, compared to 0.5-1% per year in stable post-menopause. This is the intervention window during which DEXA scans, weight-bearing exercise, and dietary and supplementation strategies have the highest leverage. It is also the window during which DEXA is routinely underused in perimenopausal women — most clinicians do not order it until after menopause is confirmed (de Villiers et al., 2024).

Joint pain and the musculoskeletal syndrome of menopause

This cluster was under-recognised for decades. In 2024, Wright and colleagues, writing in Climacteric, formally named and defined "the musculoskeletal syndrome of menopause" — a coordinated cluster of joint pain, frozen shoulder (adhesive capsulitis), plantar fasciopathy, carpal tunnel syndrome, and accelerated knee osteoarthritis driven by estrogen's loss of action on chondrocytes, synovial fibroblasts, and musculotendinous tissues. A 2026 meta-analysis of 93,021 women in the Journal of Bone and Joint Surgery confirmed: women in the transition are at significantly increased risk of developing muscle or joint pain. If you have been told your shoulder pain at 47 is just aging, the literature now disagrees.

Sexual and vaginal health — GSM

Genitourinary Syndrome of Menopause, or GSM, replaced the older term "vulvovaginal atrophy" in the clinical literature. It encompasses vaginal dryness, painful intercourse, decreased lubrication and arousal, urinary frequency and urgency, and recurrent urinary tract infections — all arising from the loss of estrogen receptor activity in urogenital tissues. Up to 84% of post-menopausal women have GSM symptoms (British Society of Sexual Medicine, 2024). Unlike hot flashes, GSM does not resolve on its own. It progresses. The clinical reality that women rarely hear: vaginal estrogen, delivered topically as a cream, ring, or tablet, has minimal systemic absorption and is appropriate even for many women who are not candidates for systemic HRT. It is the single most under-used intervention in mainstream perimenopause care.

Skin and hair

Estrogen upregulates collagen synthesis. Its loss produces a 30% reduction in skin collagen in the first five years after menopause, followed by a steady 2% annual decline. Elastin also decreases (Dominguez, HPC Today, 2025). The skin loses water-barrier function, becomes drier, heals more slowly. Hair changes are mediated by both estrogen loss and relative androgen excess — female pattern hair loss accelerates, hair follicles miniaturise, density thins.

Perimenopause vs menopause vs andropause: the three midlife transitions

Three transitions, three different biological architectures. Perimenopause is the hormonal turbulence — the years of estradiol oscillation and progesterone decline that precede the final menstrual period. Menopause is the point — twelve consecutive months without a period. The post-menopausal years that follow have their own physiology, but they are not perimenopause.

Andropause is the male equivalent in name but not in mechanism. Where perimenopause is dysregulation followed by cessation, andropause is gradual, linear, and unidirectional — testosterone declines roughly 1 to 2% per year from age 30 onward, with cumulative effects becoming clinically noticeable between 45 and 55. Andropause does not arrive as a wave. It seeps in.

The reason this matters clinically: the protocols are different. Perimenopause requires interventions that stabilise hormonal volatility and address symptoms that may shift week to week. Andropause requires interventions that address a slowly declining baseline. A framework built for one does not transfer to the other.

HRT for perimenopause: the steel-manned debate

The single most contested question in perimenopause care is whether, when, and how to use hormone therapy. The mainstream articles tend to give a tidy answer in one direction or the other. The literature is more interesting than that.

Dr. Avrum Bluming and Carol Tavris, in Estrogen Matters (2018, updated 2024), argue — citing twenty-five studies they have reviewed and the WHI re-analyses — that estrogen given in the perimenopausal and early-menopausal window confers cardiovascular benefit, bone protection, and likely cognitive protection, and that the original WHI alarm about breast cancer was substantially misinterpreted because of the age and HRT type of the original cohort. Dr. JoAnn Manson, the principal investigator of the WHI itself, has more recently published her own reappraisal that aligns directionally with Bluming on the timing hypothesis: HRT initiated within ten years of the final menstrual period or before age 60 has a different risk profile than HRT initiated later.

Dr. Jen Gunter, in The Menopause Manifesto (2021), provides the rigorous counterweight. She is sharply skeptical of compounded "bioidentical" hormones marketed beyond evidence, of supplements with weak data, and of the broader wellness industry's tendency to oversell anything that is not pharmacologically proven. Her insistence on evidence-first standards is a discipline the integrative side of this field needs.

Dr. Mary Claire Haver's clinical practice, codified in The New Menopause (2024), threads the needle: hormone therapy used where indicated, layered with the gut, cortisol, and metabolic interventions that mainstream OB-GYN typically skips. Dr. Sara Gottfried adds the precision-medicine framing — the multi-hormonal cascade where cortisol is the most common upstream driver.

The honest position is the integrated one. Modern hormone therapy, particularly transdermal estradiol paired with oral micronized progesterone, has a more favourable safety profile than the conjugated equine estrogens and synthetic progestins used in the original WHI. It is, where appropriate, one of the most effective interventions in this transition. It is also not the whole answer. The cortisol-progesterone axis, the estrobolome, the musculoskeletal syndrome, the brain glucose metabolism question — these run alongside hormone therapy, not as alternatives to it.

What the M3 framework offers, and what the integrative voices from Bluming through Haver through Gottfried through Sims agree on at the edges, is that perimenopause requires a both-and. Hormone therapy where it serves. Strength training, sleep, breath, nervous-system care, gut work, and herbal support that mainstream care underemphasises. The disagreement is real. The synthesis is also real.

Why mainstream advice on perimenopause falls short

Mainstream perimenopause care has improved meaningfully in the last five years. The Menopause Society's 2022 Hormone Therapy Position Statement reframed HRT as the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause — and emphasised that the risks of modern hormone therapy, particularly when initiated within ten years of the final menstrual period or before age 60, are low. Dr. Avrum Bluming, the male oncologist who co-authored Estrogen Matters with social psychologist Carol Tavris, has done as much as any clinician alive to clarify what the WHI data actually showed and to challenge the field's reflexive fear of estrogen.

And yet — and this is the gap the M3 framework was built to address — the dominant clinical paradigm still treats perimenopause as principally a question of whether to replace hormones. The deeper blind spots remain.

The cortisol blind spot. Most OB-GYN appointments do not assess HPA axis function. Yet chronic cortisol elevation suppresses ovarian function via GnRH inhibition, worsens the progesterone deficit, fragments sleep architecture, and drives the visceral fat shift independently of hormones. Dr. Sara Gottfried, the Harvard-trained gynecologist and author of The Hormone Cure, has built much of her clinical practice around the observation that cortisol is the most common upstream driver of perimenopausal symptom severity — and that addressing cortisol before reaching for hormones changes outcomes.

The gut blind spot. Dr. Mary Claire Haver, OB-GYN, certified menopause practitioner, and author of The New Menopause, has put gut health on the perimenopause map. The estrobolome — the subset of gut bacteria that produces beta-glucuronidase, which deconjugates estrogens in the gut — is a meaningful regulator of how much estrogen is recycled versus excreted. Dysbiosis disrupts that recycling. Marano and colleagues (2026, PMC12986310) confirmed the active research linking the gut-brain-hormone axis specifically to perimenopausal anxiety.

The muscle and exercise blind spot. Dr. Stacy Sims, the exercise physiologist and author of ROAR and Next Level, has made the case more forcefully than anyone: women are not small men, and the perimenopause exercise advice most women receive is extrapolated from male physiology or from data on sedentary older women. Her recommendation for the perimenopausal woman is heavy resistance training in the 3-5 rep range, two to three times per week, with progressive overload — to build muscle, improve insulin sensitivity, protect bone density, and support brain health. Long-duration moderate-intensity cardio, the default mainstream prescription, can worsen the cortisol dysregulation perimenopausal women already have.

The brain blind spot. Mosconi's neuroimaging work establishes that perimenopause is the front line of Alzheimer prevention in women — and yet the conversation about long-term brain protection is largely absent from mainstream perimenopause appointments. The interventions that protect the perimenopausal brain (estrogen where appropriate, strength training, sleep, stress reduction, fish oil, glucose stability) are the same interventions that protect against everything else. The framing is the gap.

The cortisol-progesterone connection: the silent driver

There is a clinical observation that has been made for decades: women with the most chaotic perimenopausal symptoms are usually women who have been carrying too much for too long. The biology is becoming clearer.

The "pregnenolone steal" hypothesis — popular in functional medicine — posits that chronic stress diverts the shared precursor pregnenolone toward cortisol production at the expense of progesterone and DHEA. The strict biochemical steal is not fully demonstrated in clean experimental settings. But the functional outcome is real, and the better-evidenced mechanism is hypothalamic. Chronic cortisol elevation suppresses GnRH pulsatility — the foundational rhythm of the HPO axis. When GnRH is suppressed, ovulation is suppressed. When ovulation is suppressed, progesterone is not produced. The result is the same as the steal hypothesis predicts, even if the mechanism is not literal substrate theft: cortisol up, progesterone down.

This matters because progesterone is not just a reproductive hormone. Its metabolite allopregnanolone modulates GABA-A receptors — providing the natural calming, sleep-supporting, anxiolytic tone that holds the perimenopausal nervous system steady. Lose progesterone, lose that tone. And when the tone is lost, the world becomes harder to inhabit even when nothing external has changed.

The practical translation is unfashionable but consistent: the most important perimenopause intervention many women can make is not a hormone. It is reducing the cortisol load. Sleep first, second, and third. Strength training over chronic cardio. Eating in alignment with the circadian rhythm. Saying less, doing less, holding less. The body in this transition is asking for a different relationship to demand.

The estrobolome: the gut-hormone axis few articles cover

The term estrobolome was coined by Claudia Plottel and Martin Blaser in Cell Host & Microbe (Plottel and Blaser, 2011) to describe the aggregate of gut microbial genes — chiefly those encoding beta-glucuronidase — that deconjugate estrogen metabolites in the gut and allow them to re-enter circulation rather than be excreted. It is, in modern endocrinology terms, the bridge between gut health and circulating estrogen exposure.

In a healthy gut, the estrobolome regulates the recycling of estrogen at a steady rate. In dysbiosis — when harmful bacteria proliferate, when fibre is low, when antibiotics or chronic stress have disrupted the microbial ecology — beta-glucuronidase activity rises, more estrogen is reabsorbed, and the body's estrogen exposure becomes erratic. In perimenopause, where estradiol is already oscillating, the estrobolome compounds the volatility.

Kwa and colleagues, in the Journal of the National Cancer Institute (Kwa et al., 2016), extended the estrobolome concept to breast-cancer-risk modulation. Baker, Al-Nakkash, and Herbst-Kralovetz in Maturitas (2017) consolidated the menopausal angle. Wang and colleagues (2026, ScienceDirect) and Saravinovska et al. (2026, PMC13082958) have since mapped the estrogen-gut microbiota axis in detail.

The applied conclusion for the perimenopausal woman is mundane and powerful: diversity of plant fibres, fermented foods where tolerated, adequate gut transit time, alcohol moderated, and unnecessary antibiotics avoided matter more than most supplement protocols. The microbiome is one of the few hormonal levers a woman can pull every day with her own hands. The Ayurvedic frame for the same terrain — agni (digestive fire) and ama (metabolic residue) — has been prescribing warm-cooked foods, triphala, and time-restricted eating against this exact pathology for two millennia. Two vocabularies, one phenomenon.

Why am I so angry? Perimenopausal rage and the allopregnanolone story

Of all the perimenopausal symptoms, the one that costs women the most in their relationships is the one that mainstream articles whisper around: the sudden, disinhibited rage. The intensity that arrives without proportionate cause. The trip-wire irritability that the woman herself finds frightening because it is not who she has been.

The mechanism is now well-characterised, though it has not yet reached most clinicians. Progesterone, in addition to its uterine role, is metabolised in the body and brain to allopregnanolone — a potent positive allosteric modulator of the GABA-A receptor and one of the most powerful endogenous anxiolytics the human body makes. The work of Torbjörn Bäckström at Umeå University in Sweden, along with Peter Schmidt at the NIH, established this mechanism over decades of premenstrual dysphoric disorder (PMDD) research. When allopregnanolone levels are stable, the GABA tone of the nervous system holds. When allopregnanolone levels fluctuate — as they do severely in PMDD, and as they do progressively in early perimenopause when ovulatory cycles falter and progesterone production becomes erratic — the GABA tone destabilises. The result, neurologically, is disinhibition: anger thresholds drop, panic thresholds drop, the ability to override an emotional impulse with executive function drops.

This is not character failure. It is endogenous benzodiazepine withdrawal at the receptor level. The Ayurvedic frame — Vata aggravation in the climacteric — describes the same lived state in different vocabulary. The two frameworks are not in conflict; they are translations of the same phenomenon.

The practical implication: the perimenopausal rage cluster responds, in clinical observation, to interventions that stabilise GABA tone — magnesium glycinate at 300 to 400 milligrams in the evening, restorative yoga (especially supta baddha konasana with weighted bolster), bhramari and nadi shodhana pranayama, abhyanga before bed, and where appropriate, micronized progesterone (which converts to allopregnanolone in the brain — this is part of why women on transdermal estradiol plus oral micronized progesterone often report not just hormone replacement but a return of nervous-system steadiness).

If you are the woman experiencing this, you are not unstable. You are inside a neurosteroid withdrawal that has a name and a mechanism. If you are someone who loves her, this is the section to read twice.

Does perimenopause cause joint pain? The musculoskeletal syndrome of menopause

This cluster was under-recognised for decades. In 2024, Dr. Vonda Wright, an orthopedic surgeon, published a paper in Climacteric (Wright et al., 2024) formally naming and defining what she termed the musculoskeletal syndrome of menopause — a coordinated cluster of joint pain (arthralgia), frozen shoulder (adhesive capsulitis), plantar fasciopathy, carpal tunnel syndrome, tendinopathy, sarcopenia, and accelerated bone loss, all driven by estrogen's loss of action on the tissues where estrogen receptors are densely expressed: chondrocytes, synovial fibroblasts, tendon, ligament, muscle, and bone.

A 2026 meta-analysis of 93,021 women in the Journal of Bone and Joint Surgery confirmed: women in the transition are at significantly increased risk of developing muscle or joint pain. Atasoy-Zeybek and colleagues (2025, npj Women's Health) reported that estrogen supplementation produces modest but sustained reductions in joint pain frequency — direct mechanistic confirmation.

If you have been told your shoulder pain at 47 is just aging, the literature now disagrees. The musculoskeletal syndrome of menopause is a defined clinical entity. The interventions that matter are the same ones that protect bone and muscle — heavy resistance training, weight-bearing impact, adequate protein, vitamin D, and where appropriate, vaginal or systemic estrogen. The Ayurvedic frame names the same terrain (vata aggravation of the joints; dryness of the sinews) and prescribes warm-oil abhyanga, sesame oil daily, and the supported yoga poses Geeta Iyengar specifically taught for this window.

Why do I wake up at 3am in perimenopause?

Almost every woman in this transition reports the same sleep signature: she falls asleep without much trouble, then wakes between 1am and 3am, often with a hot flush, sometimes with palpitations, often with a racing mind that has nowhere to land. By the time the dawn comes she has slept poorly for hours. This pattern is not random.

Three mechanisms converge at 3am. First, the cortisol rhythm. In perimenopausal HPA dysregulation, the cortisol nadir that should hold across the first half of the night is shallower and earlier than it should be — cortisol begins rising too soon, and the sleep system loses its anchor. Sahola and colleagues (Maturitas, 2024) demonstrated that worse objective sleep architecture in perimenopausal women correlates directly with higher cortisol levels. Second, the progesterone-allopregnanolone deficit. Without the GABA-stabilising effect of allopregnanolone, the nervous system loses its sedating tone. Third, the thermoregulatory window. The KNDy-driven hot flash architecture peaks in the small hours; what wakes the woman may be a vasomotor event so mild she does not register it as a hot flash.

The practical sequence that works in clinical practice: address cortisol first (afternoon protein, ashwagandha, magnesium glycinate before bed, dark cool room, consistent wake time), address allopregnanolone where appropriate (micronized progesterone in some women, glycine and L-theanine in others), address thermoregulation with viparita karani in the evening, bhramari before sleep, and a cool bedroom. The compound effect of these is larger than any of them alone. Most women begin to sleep through the night within three to six weeks.

How do I know if I am in perimenopause or just stressed?

This is the question that most often arrives in retreat conversation. The answer requires holding two truths simultaneously. The first: chronic stress and the early perimenopausal transition produce overlapping symptom profiles, because they share a mechanism — cortisol elevation that suppresses GnRH pulsatility and disrupts ovulatory progesterone production. The HPA-HPO crosstalk means that stress can produce a clinical picture that looks indistinguishable from early perimenopause, and early perimenopause is amplified by stress. The two are not separate problems with separate solutions.

The second truth: there are specific markers that point toward perimenopause as the underlying driver. Irregular cycles in a woman over 40 who has had decades of regular cycles. New-onset hot flashes or night sweats. Vaginal dryness or new urinary urgency. Brain fog and word-finding difficulty that worsens around the period. A new pattern of waking at 3am. Joint pain on rising that was not there a year ago. Hair thinning, particularly at the temples. The musculoskeletal cluster Wright described. Any of these in combination tilt the diagnosis toward perimenopause rather than pure stress.

The third truth: it is rarely either-or. Most women in this window are inside both at once. The framework that helps is one that addresses both axes simultaneously — cortisol load and hormonal transition — without forcing a single diagnostic label. The M3 System is built for the overlap, not for the either-or.

The Ayurvedic view: Rajonivritti, Artava Kshaya, and the Vata transition

Ayurveda named this transition before modern endocrinology existed. The classical term for menopause itself is Rajonivritti — from rajah (menstrual blood, or more broadly, the Artava reproductive essence) and nivritti (cessation). Literally, the cessation of menses.

There is no single classical Sanskrit term that corresponds exactly to the modern construct of perimenopause as a defined transitional window. What the classical texts describe instead is Artava Kshaya — the depletion of Artava, the reproductive essence — within the broader Vata avastha, the Vata-dominant phase of life that begins around age 50. Charaka, in the Chikitsa Sthana of his Samhita, places the cessation of menses at approximately 50 years. Sushruta describes Artava itself in the Sutra Sthana (Chapter 14) and the Sharira Sthana (Chapter 3). Vagbhata's Ashtanga Hridayam addresses the same ground.

The Ayurvedic life-stage model maps the transitions of all human life through the three doshas: Kapha avastha (childhood), Pitta avastha (adulthood, roughly 16 to 50), and Vata avastha (after 50). The shift from Pitta to Vata is the perimenopause window. But the female body experiences it differently than the male body, and this is where contemporary Ayurvedic practitioners like Vaidya Vasant Lad at the Ayurvedic Institute in Albuquerque, and Dr. Claudia Welch in her book Balance Your Hormones, Balance Your Life, have added nuance.

For women, the Pitta-to-Vata transition does not arrive cleanly. Three doshic patterns commonly appear, and women in the transition often cycle through all three.

Vata aggravation (vata prakopa). The dominant pattern. Dryness of vaginal tissues, skin, joints. Insomnia. Anxiety. Irregular cycles. Restlessness. Palpitations. This is the pattern that demands grounding, warmth, oil, and ritual.

Pitta aggravation. In women of pitta constitution (prakriti), the transition expresses through hot flashes, irritability, rage, heavy bleeding, and inflammatory skin changes. The intervention is cooling — bitter greens, coconut oil, cooling herbs.

Kapha-Vata mixed. Weight gain, sluggish digestion, and depression alongside vata symptoms. The intervention is gentle activation and metabolic kindling.

Classical Ayurveda is therefore not a single perimenopause prescription. It is a constitutional system. The same transition asks different things of different women.

Ayurvedic herbs for the female mid-life transition

The classical Ayurvedic pharmacopoeia includes a specific category of herbs called stree rasayana — rejuvenatives for the female reproductive system. The most important are listed below, with their classical indication and the modern dose ranges supported by contemporary Ayurvedic clinical literature and recent randomised trials.

Shatavari (Asparagus racemosus)

The queen of women's herbs in Ayurveda. Charaka's Chikitsa Sthana lists shatavari as a primary stree rasayana and vajikarana herb. The Bhavaprakasha Nighantu, the 16th-century materia medica, groups it among the foundational Guduchyadi herbs. Classical indications: promotes Stanya (lactation), regulates Artava, builds Ojas (vital essence), pacifies both Pitta and Vata.

The modern evidence has caught up. Pingali and colleagues (2025, PMC12070120) ran a randomised, double-blind, placebo-controlled trial showing that shatavari and ashwagandha extracts dose-dependently reduced menopausal symptoms, vascular dysfunction, and bone resorption in postmenopausal women. Mahajan et al. (2025, PMC12593836) ran the trial specifically on perimenopausal women: shatavari root extract was both effective and safe. Higher-dose groups in the Ademola et al. (2025) trial experienced 77.3% improvement in somatic symptoms — hot flushes and sleep — over 120 days.

Modern dose range: 3 to 6 grams of root powder daily, or 250 to 500 milligrams of standardised extract twice daily.

Ashoka (Saraca asoca)

Described in both Charaka and Sushruta under Stree Roga. The name itself means "remover of sorrow." Primary classical uses: menorrhagia, dysmenorrhea, fibroid-related bleeding, irregular cycles — precisely the early-perimenopause heavy bleeding pattern. Pacifies Pitta and Kapha. The classical preparation Ashokarishta, a fermented decoction, remains one of the most widely used Ayurvedic formulations for women in this window.

Modern dose range: 3 to 6 grams of bark powder daily, or 250 to 500 milligrams of standardised extract twice daily.

Vidari Kanda (Pueraria tuberosa)

Charaka groups it under rasayana and vrishya (vitality) herbs. Contains phytoestrogens of the puerarin family — the same chemical class found in kudzu. Bhavaprakasha lists it alongside shatavari as a stree rasayana. The modern conceptual overlap with soy isoflavones makes vidari a culturally distinct but biologically related phytoestrogen option for women who prefer to avoid soy.

Modern dose range: 3 to 6 grams of tuber powder daily, or 250 to 500 milligrams of extract twice daily.

Lodhra (Symplocos racemosa)

Described in Sushruta's Uttara Tantra and the Bhavaprakasha for asrigdara — uterine bleeding disorders. Astringent in action; reduces excessive menstrual flow. Used in the early perimenopause heavy-bleeding pattern, typically combined with ashoka in classical formulations.

Modern dose range: 3 to 6 grams of bark powder daily.

Ashwagandha (Withania somnifera) — women-specific dosing

Classically associated with male vajikarana, but Charaka lists it among the premier rasayana herbs and modern Ayurvedic practice uses it extensively in women for stress, sleep, and adrenal support. Its primary mechanism in this context is HPA modulation — cortisol lowering — which makes it the natural herb for the cortisol-progesterone axis problem at the heart of perimenopause.

Modern dose range for women: 300 to 600 milligrams per day of standardised root extract (KSM-66 or Sensoril), for 8 to 12 weeks. Vani and colleagues (2025, Frontiers in Reproductive Health) confirmed efficacy specifically in healthy women in the menopausal transition.

Brahmi (Bacopa monnieri)

Charaka's premier medhya rasayana — the cognitive rejuvenative. The natural herb for the brain fog cluster. Robust RCT evidence in non-perimenopausal populations for memory, working memory, and reduction of anxiety. The 30% drop in brain glucose metabolism Mosconi documents during perimenopause is one of the strongest arguments for a cognition-targeted intervention in this window — and brahmi is the classical option.

Modern dose range: 300 to 600 milligrams per day of standardised extract (containing at least 20% bacosides), for 8 to 12 weeks.

Several classical Ayurvedic formulations combine these single herbs for the perimenopausal pattern. Ashokarishta — for menorrhagia and irregular cycles. Chandraprabha Vati — for urinary, vaginal, and pelvic symptoms. Phala Ghrita — medicated ghee for Artava Kshaya. Saraswatarishta — for the anxiety and cognitive cluster. These are practitioner-prescribed; they are not substitutes for clinical assessment, but they are part of the working pharmacopoeia of any contemporary Ayurvedic practitioner who treats women in this transition.

Abhyanga: the daily oil massage that touches the cortisol-progesterone axis

The Ashtanga Hridayam, in the Sutra Sthana, Chapter 2 on Dinacharya (daily routine), describes abhyanga as essential: practiced regularly, it alleviates Vata, removes fatigue, promotes good sleep, strengthens the skin, and supports longevity. Charaka makes the same case in his Sutra Sthana, Chapter 5. The protocol is simple. The mechanism is now better understood than it was twenty centuries ago.

For vata pacification in perimenopause, the classical recommendation is daily warm sesame oil — applied to the body before the bath, with long strokes on the long bones and circular strokes on the joints, for at least ten to fifteen minutes. The modern correlate of why this works: the warm oil and slow rhythmic touch activate C-tactile afferents — a specific population of skin nerve fibres that signal directly to the insula and modulate parasympathetic tone. The result is measurable cortisol reduction. Abhyanga is, in modern language, a direct intervention on the cortisol-progesterone axis. The Ayurvedic tradition simply named it differently.

For pitta-aggravated women — hot flashes, irritability, inflammatory skin — coconut oil or bhringraj oil replaces sesame, and the contact time shortens. The principle holds. The medium adapts to the constitution.

Traditional Chinese Medicine: the seven-year cycles and Kidney essence

Twenty-three centuries ago, the Huangdi Neijing Su Wen — the Yellow Emperor's Inner Canon, the foundational text of Chinese medicine — opened with a description of women's reproductive lifespan as a series of seven-year cycles driven by Kidney Qi and Tian Gui (Heavenly Water — the reproductive essence). The passage, in the first chapter, reads, in paraphrase: at 14, Tian Gui arrives, the Ren and Chong meridians open, menstruation begins. At 28, the body is at peak strength. At 35, the Yangming channels weaken — the face begins to dry, hair begins to fall. At 42, three yang channels weaken in the upper body. At 49, the Ren and Chong empty, Tian Gui exhausts, menstruation ends.

The 35 to 49 window — from Yangming weakening to Tian Gui exhaustion — maps with surprising precision onto the modern STRAW staging of perimenopause. The Inner Canon described it as a recognisable phase of life with its own physiology more than two thousand years before STRAW.

In contemporary TCM practice, perimenopausal women present with one or several of five overlapping patterns. The most common — and the one that explains hot flashes most cleanly — is Kidney Yin Deficiency. Yin is the cooling, moistening, substantive aspect; when it depletes, it can no longer anchor Yang, and Yang rises uncontrolled. The classical mechanism of Empty Heat. The clinical signs: hot flashes, night sweats, dry mouth, malar flush, insomnia, low back ache, tinnitus, red tongue with little coat, thin rapid pulse.

Liver Qi Stagnation is the pattern of chronic stress and emotional suppression — extremely common in modern perimenopausal women. The Liver, in TCM, stores Blood and governs the smooth flow of Qi. When Qi stagnates, the result is irritability, mood swings, PMS, breast tenderness, side-of-head headaches. When stagnant Qi transforms into Heat — Liver Qi rising into the face — the result is rage, red eyes, severe insomnia, vivid dreams. This is the classical TCM explanation of perimenopausal rage, and the formula traditionally prescribed for it, Jia Wei Xiao Yao San (Augmented Free and Easy Wanderer), remains a workhorse in contemporary clinical practice.

Heart-Kidney Disharmony — the pattern when Kidney Yin can no longer rise to nourish the Heart, and Heart Fire can no longer descend to warm the Kidneys — produces the severe perimenopausal insomnia that wakes women at 1 to 3am, with palpitations, anxiety, vivid dreams, and dry mouth. The classical formula is Tian Wang Bu Xin Dan, the Heavenly Emperor Tonify the Heart Pill, from the Ming Dynasty.

The foundational TCM formula for the Yin deficiency root, Liu Wei Di Huang Wan — Six-Ingredient Pill with Rehmannia — was written by Qian Yi during the Song Dynasty, around 1119 CE, in a pediatric text and adopted later for adult Kidney Yin deficiency. Zhu and colleagues (2016, PMC4951187) summarised the modern literature on its use in menopause: more than one thousand years of clinical record, and the most-studied TCM formula for the menopausal transition globally.

TCM also has a dietary therapy. The classical principle for the perimenopausal pattern is to nourish Yin and gently warm Yang — warm cooked foods, slow simmering, soups and congees. The foods that correspond to the Kidney organ in TCM are black: black beans, black sesame, black rice, wood ear mushrooms, mulberries. Seafood, eggs, bone broths, dark leafy greens, goji berries, jujube. The foods to reduce: spicy and hot foods that aggravate empty heat, cold raw foods that damage the Spleen, refined sugar that creates damp-heat. This aligns directly with the Ayurvedic vata-pacifying principle, and both align with the modern advice on stable blood sugar and circadian-aligned eating. Three traditions, one conclusion.

Yoga for perimenopause: the shift from heating to cooling

The classical householder yoga model recognises that practice changes with the life stage. The transition from grihastha (the householder phase) into vanaprastha (the forest-dweller, contemplative phase) traditionally begins around age 50 — precisely the perimenopause window. The implication is that the practice itself is meant to shift in this decade.

No teacher has done more to specify what that shift looks like for women than Geeta Iyengar. Daughter of BKS Iyengar, principal author of the Iyengar method's women's tradition, and author of Yoga: A Gem for Women — published in 1983, with a foreword by her father — she designed specific sequences for menstruation, pregnancy, post-partum, and menopause. Her teaching: during the menopausal transition, practice must shift from heating to cooling, from active to restorative, from forward bends and inversions held actively to supported and longer holds. Her work was extended posthumously in Geeta S. Iyengar's Guide to a Woman's Yoga Practice (Vol. I), edited by Lois Steinberg, and is the most refined reference text on yoga for the female reproductive lifespan in English.

A short sequence for perimenopause, drawn from this tradition.

Supta Baddha Konasana (reclined bound angle pose)

Geeta Iyengar specifically prescribed this pose for women in the transition. Supported with a bolster under the spine and blocks or blankets under the outer thighs, held for five to fifteen minutes, it produces deep parasympathetic activation, releases pelvic tension, calms hot flashes when held cool, and supports sleep.

Viparita Karani (legs-up-the-wall)

The closest yoga equivalent to a sleeping pill. Held passively for ten to twenty minutes in the evening, with the legs against the wall and an optional bolster under the sacrum, viparita karani lowers heart rate and blood pressure, reverses venous return, and directly addresses the perimenopausal sleep-architecture problem. The single most reliably effective asana for insomnia.

Setu Bandha Sarvangasana (bridge pose)

Supported with a block or bolster under the sacrum, held for five to ten minutes — the restorative variant Geeta Iyengar specifies — stimulates the thyroid via gentle chin lock, supports vagal tone, helps mild depression and fatigue, releases the lower back. Useful for the perimenopausal woman with sluggish thyroid function, common in this window.

Janu Sirsasana (head-to-knee pose)

A cooling asana in BKS Iyengar's heating-cooling classification — particularly when the forehead is supported on a bolster or block. Calms irritability, restless mind, and digestive sluggishness. The forward fold provides gentle vagal stimulation.

Balasana and Savasana

Child's pose for grounding through the day. Savasana — corpse pose — for fifteen to twenty minutes minimum at the end of any practice, longer for deep restoration. Every perimenopausal symptom benefits from regular savasana. The cumulative effect on cortisol and autonomic balance is measurable.

Breathwork for perimenopause: pranayama for thermoregulation and vagal tone

Nadi Shodhana — alternate nostril breathing. The single most-prescribed pranayama for perimenopause. Balances the cooling-lunar (ida) and heating-solar (pingala) channels — the autonomic balancing of sympathetic and parasympathetic tone in modern language. Five to ten minutes morning and evening. Has been shown in small trials to reduce cortisol and improve heart rate variability.

Sheetali — cooling breath. Inhale through a curled tongue (or, if the tongue does not curl, through pursed lips — sheetkari). The active intervention for a hot flash in real time. Geeta Iyengar specifically recommended sheetali for menopausal heat. Can be used in the moment of a hot flash with measurable effect.

Bhramari — humming bee breath. A humming exhale that activates vagal afferents at the soft palate and releases nitric oxide in the sinuses. For anxiety, racing mind, irritability, insomnia. The evening practice.

Ujjayi — ocean breath. A slight glottal constriction that lengthens both inhale and exhale. Supports the deep, anchored breathing that the anxious-irritable perimenopausal woman often loses. Pairs with restorative asana.

Strength training for perimenopause: the intervention every woman over 40 should know

If there is one mainstream blind spot the perimenopausal woman should correct first, it is this: heavy resistance training is not optional in this window. It is foundational. The reasons compound. Estrogen has direct anabolic signaling on skeletal muscle via estrogen receptors on satellite cells; its decline accelerates muscle loss unless something else picks up the signal. That something is mechanical load.

Dr. Stacy Sims's recommendation, distilled from the contemporary exercise physiology literature: heavy resistance training in the 3 to 5 rep range, two to three times per week, full body, with progressive overload. Not 8 to 12 reps. Heavy, neural-drive training. The benefits cascade: muscle mass, basal metabolic rate, insulin sensitivity, bone mineral density, cognitive function, mood. Zhao and colleagues (2025, PMC12107943) confirmed in a meta-analysis that the combination of resistance training and impact loading produces the largest bone density improvements in this window. Xiaoya et al. (2025) ranked combined resistance + jumping training highest in a network meta-analysis of exercise modalities for postmenopausal bone health.

Sprint intervals — true HIIT at greater than 90% effort, in efforts of under 90 seconds — are the cardiovascular complement. Long zone-2 cardio, the mainstream prescription, often worsens the cortisol pattern in perimenopausal women whose HPA axis is already stressed. The training model that works in this window is closer to that of a competitive athlete than that of a recreational walker.

Sleep, circadian rhythm, and the perimenopausal nervous system

Sleep is the foundational metabolic intervention of this transition. The reasons are mechanical. Sleep regulates cortisol pulse architecture, growth hormone release, glucose disposal, glymphatic clearance of metabolic waste from the brain, and the consolidation of emotional memory. Each of these is impaired by perimenopausal sleep disruption — and each, when restored, addresses a symptom cluster more efficiently than any supplement.

The applied protocol is unfashionable but consistent. Dark room. Cool room — the thermoregulatory dysfunction of perimenopause is amplified by warmth. Consistent sleep and wake times anchored to sunlight exposure in the morning. Largest meal at midday rather than the evening, in line with both circadian metabolism research and the Ayurvedic principle of agni peaking in the middle of the day. Caffeine cut-off by early afternoon. Alcohol minimised — its impact on REM and on hot flash frequency is now well-documented.

When restorative practices are added at the perimeter — viparita karani in the evening, bhramari before sleep, magnesium glycinate before bed, ashwagandha for the cortisol-driven sleep collapse — the architecture of the night begins to repair itself. The improvements compound week by week.

Perimenopause and intimacy: the conversation no one is having

Genitourinary Syndrome of Menopause affects up to 84% of post-menopausal women and a meaningful proportion of perimenopausal women — and most of them have never discussed it with a clinician. The symptoms — dryness, painful intercourse, decreased lubrication and arousal, urinary frequency and urgency, recurrent urinary tract infections — arise from estrogen receptor loss in urogenital tissues. Unlike hot flashes, which often improve with time, GSM is progressive. It worsens.

The clinical reality that women rarely hear: topical vaginal estrogen — cream, ring, or tablet — has minimal systemic absorption and is appropriate even for many women who are not candidates for systemic hormone therapy. The AUA/SUFU/AUGS Guideline on GSM (Kaufman et al., 2025) and the Fifth International Consultation on Sexual Medicine (Simon et al., 2026) both place vaginal estrogen as a first-line intervention. It is one of the most under-used effective interventions in mainstream perimenopause care.

The Ayurvedic and TCM traditions address the same terrain through different language. Yoni pichu — the classical Ayurvedic practice of placing medicated ghee or sesame oil internally — addresses local dryness directly. Restorative pelvic-floor yoga, particularly the supta poses, supports the parasympathetic tone that local circulation depends on. The integration is not either-or. The framework holds vaginal estrogen and ancient practices simultaneously, because both serve the woman.

What herbs and supplements help with perimenopause symptoms? A specific dose grid

What follows is the dose grid the contemporary literature supports, drawn from the most-cited recent trials and the classical Ayurvedic pharmacopoeia. None of this replaces clinical assessment. All of it is what I have watched move the needle in retreat and 1:1 practice when matched to the right pattern in the right woman.

Magnesium glycinate. 300 to 400 milligrams in the evening. Supports GABA tone, sleep architecture, and muscle relaxation. The form matters — glycinate is better absorbed and less laxative than oxide.

Omega-3 (EPA + DHA). 1 to 2 grams per day. Supports brain glucose metabolism, joint inflammation, and mood. Higher end of range for women with depressive symptoms.

Vitamin D3. 1,000 to 2,000 IU per day, ideally with K2. Bone, muscle, mood, immune function. Adjust based on serum 25-hydroxy levels.

Creatine monohydrate. 3 to 5 grams per day. Now supported by multiple trials in midlife women for muscle, bone, cognitive performance, and mood. The single most under-used supplement for women in this window.

Protein. 1.6 to 2.2 grams per kilogram of body weight per day, distributed across meals with at least 30 grams at each. Protects muscle, supports satiety, stabilises blood sugar. The mainstream RDA of 0.8 g/kg is calibrated to prevent deficiency, not to support optimal aging in women.

Shatavari. 3 to 6 grams of root powder daily, or 250 to 500 milligrams of standardised extract twice daily. RCT-supported (Pingali 2025; Mahajan 2025).

Ashwagandha (KSM-66 or Sensoril). 300 to 600 milligrams per day for 8 to 12 weeks. Cortisol modulation; particularly for the anxiety-and-sleep cluster.

Brahmi (Bacopa monnieri). 300 to 600 milligrams of standardised extract per day (at least 20% bacosides) for 8 to 12 weeks. For the cognitive cluster — brain fog, memory, working-memory lapses.

Triphala. 1 to 2 grams of the classical three-fruit Ayurvedic preparation, taken with warm water in the evening. Supports the gut-estrobolome axis without disrupting microbiome diversity.

Black cohosh (Cimicifuga racemosa). 20 to 40 milligrams of standardised extract daily. Modest evidence for hot flashes; consider if you do not tolerate or do not want HRT.

Chasteberry (Vitex agnus-castus). 20 to 40 milligrams of standardised extract daily. Most useful in early perimenopause for cycle irregularity and breast tenderness.

Foods that nourish the kidney-yin pattern in TCM dietary therapy — black sesame, black beans, black rice, mulberries, wood ear mushrooms, bone broths, goji berries, jujube — overlap meaningfully with foods that support the estrobolome and stable blood sugar in modern terms. Three frameworks, one direction.

The M3 framework applied to perimenopause

The M3 System — Mindset, Movement, Metabolism — is the framework I built because the women I worked with needed one. Three integrated pillars, each addressing what mainstream care misses.

Mindset. The neurobiology of this transition does not respond to willpower. Cortisol does not lower because you decide to be less stressed. The practices that work are the ones that change the autonomic state directly — pranayama, restorative yoga, abhyanga, deep restorative sleep, and a deliberate reduction in the load a woman is carrying. The Stoic frame helps: there is what you can change, and there is the body you are in now. Acceptance of the second is the precondition for working effectively on the first.

Movement. Heavy resistance training two to three times per week. Sprint intervals. Restorative yoga from the Geeta Iyengar tradition. Walking — daily, outdoors, with morning sunlight. The combination protects muscle, bone, brain, mood, and metabolic flexibility in ways that no single modality does.

Metabolism. Protein-forward eating, with the largest meal at midday. Stable blood sugar through the day. Time-restricted feeding aligned with the circadian rhythm — a twelve to thirteen hour overnight fast, not aggressive intermittent fasting that worsens cortisol. Fibre diversity for the estrobolome. Sleep as the foundational metabolic intervention. Targeted Ayurvedic herbs — shatavari, ashwagandha, brahmi — at clinically supported doses.

What the M3 framework adds that single-discipline approaches do not: the recognition that perimenopause is a whole-system transition, that the cortisol-progesterone axis is the silent driver beneath the symptom clusters, that the ancient systems have addressed this transition for longer than modern medicine has existed, and that the integration of all three pillars produces compounding effects no single intervention matches.

A note from Marius

The women I have sat with in this transition have, almost without exception, been told the same things. That their symptoms are stress. That they are too young for perimenopause. That weight gain is normal and they should just eat less. That brain fog is age. That joint pain is age. That hot flashes will pass. That sleep disruption is part of life. That hormone therapy is dangerous, or only for women who cannot manage without it. They have been given antidepressants for what is a neurobiological consequence of progesterone loss. They have been given sleeping pills for what is a thermoregulatory and cortisol problem. They have been given anti-inflammatories for what is an estrogen-receptor mediated change in cartilage and synovium.

What the framework offers is not a cure. There is nothing to cure. Perimenopause is a transition, not a disease — Ayurveda has insisted on this for two millennia. What the framework offers is permission. Permission to take the transition seriously. Permission to slow down. Permission to redesign the way the body is fed, moved, rested, and held. Permission to use modern hormone therapy where it serves, ancient herbs where they serve, and the deep restorative practices where they serve — without choosing one tradition over another.

You are not getting older alone. There is a framework for this. The women who have walked into one of our retreats exhausted and walked out steadied did not do it on willpower. They did it inside a system that was designed for the body they were actually in. That is what this article is. That is what The M3 System is.

— Marius

Where to go from here

→ Register for the free masterclass: mariuskoller.com/masterclass

→ Learn about the 4-Week M3 Reset: mariuskoller.com/reset

→ The M3 retreats in Marbella: mariuskoller.com/retreat

→ Read the companion piece on andropause for men: mariuskoller.com/journal/andropause-the-hormonal-transition-men-are-still-not-talking-about

References and further reading

Rance, N. E. et al. (2013). Neurokinin B and the hypothalamic regulation of reproduction. Frontiers in Neuroendocrinology.

Lederman, S. et al. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1 and SKYLIGHT 2). The Lancet.

Sood, R. et al. (2013). Paced breathing compared with usual breathing for hot flashes. Menopause (Mayo Clinic randomised trial).

Plottel, C. S. and Blaser, M. J. (2011). Microbiome and malignancy / the estrobolome. Cell Host & Microbe.

Kwa, M. et al. (2016). The intestinal microbiome and estrogen receptor-positive female breast cancer. Journal of the National Cancer Institute.

Baker, J. M., Al-Nakkash, L., and Herbst-Kralovetz, M. M. (2017). Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas.

Bäckström, T. et al. Allopregnanolone and mood disorders — body of work on PMDD and perimenopausal mood through Umeå University.

Schmidt, P. J. et al. Allopregnanolone and the hormonal basis of premenstrual and perimenopausal mood disorders — NIH research programme.

Wright, V. J. et al. (2024). The musculoskeletal syndrome of menopause. Climacteric, 27(5).

Atasoy-Zeybek, A. et al. (2025). The intersection of aging and estrogen in osteoarthritis. npj Women's Health.

Panay, N. et al. (2024). White Paper on the perimenopausal transition. Climacteric, 27(5).

Gibson, C. J. et al. (2024). Epidemiology and clinical outcomes of vasomotor symptoms. Menopause, 64(9). (SWAN data on median duration of vasomotor symptoms.)

Choudhary, P. et al. (2025). Prevalence of menopausal symptoms in perimenopausal women. PMC12431706.

Santoro, N. et al. (2016). Perimenopause: From Research to Practice. Journal of Women's Health, PMC4834516.

Grub, J. et al. (2021). Hormonal fluctuations in perimenopause. PMC8712488.

Mosconi, L. et al. (2021). Menopause impacts human brain structure, connectivity, and energy metabolism. Scientific Reports (PMC8190071).

Mosconi, L. (2026). Women's midlife: the front line of Alzheimer prevention. JCI.

Hynd, M. et al. (2024). Estradiol modulates resting-state connectivity in perimenopausal depression. PMC12035911.

Troìa, L. et al. (2025). Sleep Disturbance and Perimenopause: A Narrative Review. PMC11901009.

Sahola, N. et al. (2024). Sleep architecture and cortisol in perimenopause. Maturitas.

Cho, Y. et al. (2025). Risk of Sarcopenic Obesity Across Menopausal Transition. PMC12567333.

Pingali, U. et al. (2025). Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms. PMC12070120.

Mahajan, S. et al. (2025). Shatavari root extract in perimenopausal women. PMC12593836.

Vani, I. et al. (2025). Ashwagandha root extract in the menopausal transition. Frontiers in Reproductive Health.

Zhao, F. et al. (2025). Optimal resistance training parameters for improving bone mineral density. PMC12107943.

The Menopause Society (2022). Hormone Therapy Position Statement. Menopause.

The Menopause Society (2023). Non-Hormone Therapy Position Statement. Menopause.

Bluming, A. and Tavris, C. Estrogen Matters (book; 2018, updated 2024).

Haver, M. C. The New Menopause (book; 2024).

Mosconi, L. The Menopause Brain (book; 2024).

Sims, S. ROAR and Next Level (books).

Gottfried, S. The Hormone Cure (book).

Gunter, J. The Menopause Manifesto (book; 2021).

Welch, C. Balance Your Hormones, Balance Your Life (book).

Iyengar, B. K. S. Light on Yoga (1966).

Iyengar, G. S. Yoga: A Gem for Women (book; 1983, expanded editions through 2002).

Iyengar, G. S. Geeta S. Iyengar's Guide to a Woman's Yoga Practice, Vol. I, edited by Lois Steinberg.

Lasater, J. H. Relax and Renew: Restful Yoga for Stressful Times.

Maciocia, G. Obstetrics and Gynecology in Chinese Medicine (book).

Huangdi Neijing Su Wen, Chapter 1 (Shang Gu Tian Zhen Lun) — the seven-year female reproductive life cycle.

Qian Yi (Song Dynasty, ~1119 CE), Xiao'er Yao Zheng Zhi Jue — the codification of Liu Wei Di Huang Wan.

Zhang Jiebin (Ming Dynasty), Jingyue Quanshu — You Gui Wan and Zuo Gui Wan formulas.

Fu Qingzhu (1607–1684), Fu Qingzhu Nü Ke — the canonical TCM gynecology text.

Charaka Samhita, Chikitsa Sthana and Sutra Sthana.

Sushruta Samhita, Sutra Sthana 14 and Sharira Sthana 3.

Vagbhata, Ashtanga Hridayam, Sutra Sthana 2 (Dinacharya Adhyaya) and Sharira Sthana.

CCRAS (Central Council for Research in Ayurvedic Sciences) monograph (2024), Menopausal syndrome (Rajonivritti Janya Lakshana).

This article is for educational purposes and is not medical advice. Consult a qualified physician before changing any treatment, supplementation, or lifestyle programme.